Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
$9.68
$0.61
$24.20
$820K1.4119,299 shs416,900 shs
BioCardia, Inc. stock logo
BCDA
BioCardia
$2.11
+1.4%
$2.30
$1.63
$4.66
$10.98M0.81275,863 shs3.04 million shs
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
$1.36
$1.25
$11.80
$2.54M2.37127,289 shs23,000 shs
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
$1.76
$1.08
$2.45
$131.12M1.19514,103 shs269,400 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
0.00%0.00%0.00%0.00%0.00%
BioCardia, Inc. stock logo
BCDA
BioCardia
0.00%-1.86%-0.94%+4.98%-29.43%
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
3.9842 of 5 stars
3.85.00.00.03.82.50.6
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
0.00
N/AN/AN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
3.50
Strong Buy$25.001,084.83% Upside
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
0.00
N/AN/AN/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
$117.63M0.00N/A0.02($127.17) per share0.00
BioCardia, Inc. stock logo
BCDA
BioCardia
$3K3,641.86N/AN/A$0.18 per share11.72
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/AN/AN/AN/A($3.81) per shareN/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
$350K0.00N/AN/A$1.54 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%N/A
BioCardia, Inc. stock logo
BCDA
BioCardia
-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
-$50.39M-$0.90N/AN/AN/AN/A-56.92%-43.87%N/A

Latest BVXV, BCDA, LIFE, and ACOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.39-$0.59-$0.20-$0.59N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
N/AN/AN/AN/AN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/AN/AN/AN/AN/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
3.07
0.33
0.26
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
0.36
0.36
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/A
4.12
4.12
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
0.02
6.07
6.07

Institutional Ownership

CompanyInstitutional Ownership
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
12.71%
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
11.83%
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
61.72%

Insider Ownership

CompanyInsider Ownership
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
2.60%
BioCardia, Inc. stock logo
BCDA
BioCardia
20.00%
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
6.03%
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
1111.24 million1.21 millionNo Data
BioCardia, Inc. stock logo
BCDA
BioCardia
405.18 million4.14 millionOptionable
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
331.87 million1.76 millionNot Optionable
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
5669.01 million66.46 millionOptionable

Recent News About These Companies

Pampa Metals Upsizes LIFE Offering to $6m
Pampa Metals Announces $5 million LIFE Offering
aTyr: Promising Data, But Cash May Be An Issue
Argyle Closes C$1 Million LIFE Offering
Argyle Announces up to C$1 Million LIFE Offering
Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5?
aTyr Pharma (ATYR) Receives a Buy from Wells Fargo
aTyr Pharma director buys $15K in common stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Acorda Therapeutics stock logo

Acorda Therapeutics NASDAQ:ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

BioCardia stock logo

BioCardia NASDAQ:BCDA

$2.11 +0.03 (+1.44%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$2.09 -0.02 (-0.95%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

BiondVax Pharmaceuticals stock logo

BiondVax Pharmaceuticals NASDAQ:BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

aTyr Pharma stock logo

aTyr Pharma NASDAQ:LIFE

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.